TrialThe Lancet. Oncology2025
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial.
Neeraj Agarwal et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
15 papers cite it
this paperpooled itcites it